Drugs / M5
M5
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT01694381 | Sep → Oct 2012 | ischemic stroke | TSI, LLC | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | M5 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01694381 ↗ |
| Known as | Mutant pro-urokinase | “Mutant pro-urokinase (M5)” NCT01694381 ↗ |
| Known as | Mutant proUK | “Mutant proUK, M5, was specifically designed to improve the plasma stability of single-chain proUK” NCT01694381 ↗ |
| Modality | Protein / enzyme biologic | “single point mutant of serine protease prourokinase” NCT01694381 ↗ |